POINT Biopharma Global Inc.

POINT Biopharma Global Inc. filed an 8-K with the SEC on March 15, 2021, under the ticker RACA, disclosing a material development related to its de-SPAC business combination. The filing marks a key milestone in POINT Biopharma's path to becoming a publicly traded radiopharmaceutical company focused on oncology therapeutics. The SPAC vehicle associated with RACA completed its IPO in 2020 and targeted the healthcare and life sciences sector. POINT Biopharma's pipeline centers on targeted cancer treatments using radioligand therapy, placing it within the high-growth precision oncology space. Sign up for full data, filings history, and deal analytics on SpacDesk.